Best Oncology Companies in Jiangsu, China
The 45 best Oncology companies in Jiangsu, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abogen Biosciences.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Jiangsu
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Abogen Biosciences 🦄 Developer of mRNA-based therapeutics for cancer and infectious diseases 55Moat top 14%Patents top 17%Innovation top 22%Funding top 27% All 8 signals ▾Moattop 14% Patentstop 17% Innovationtop 22% Fundingtop 27% Talenttop 38% Marketbottom 44% Globalbottom 43% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $1.1B | 51 mo ago | Series C | Dr InBev Co-Founder & Co-CEO | — | 157 patents Lipid nanoparticle delivery platforms for mRNA and circular RNA therapeutics | — |
| 2 | Innovent Bio Developer of antibody therapeutics for multiple diseases | $535M | 48 mo ago | Public | Michael Yu Founder & CEO | 5,144 | — | 1 partnership |
| 3 | Genecast Non-invasive diagnosis and monitoring of cancer | $246M | 69 mo ago | Series E | Ma Guosheng Co-Founder & VP | — | — | 1 job opening · 1 partnership |
| 4 | Souzhou Ribo Life Science Developer of nucleic acid drugs based on RNA interference (RNAi) technology | $201M | 48 mo ago | Public | Zicai Liang Founder | 228 | — | — |
| 5 | IASO BIO Provider of pharmaceuticals for cell therapies for oncology | $178M | 43 mo ago | Series C | Jinhua Zhang Co-Founder & CEO | 400 | — | — |
| 6 | Alphamab Oncology 🦄 Developer of antibodies for the treatment of cancer diseases | $160M | 86 mo ago | Public | — | 31 | — | — |
| 7 | Adagene Developer of immunotherapy for the treatment of cancer 37Funding top 18%Product top 24%Moat top 38%Tech top 42% All 12 signals ▾Fundingtop 18% Producttop 24% Moattop 38% Techtop 42% Globaltop 43% Partnerstop 45% Patentstop 46% Talentbottom 49% Growthbottom 42% Innovationbottom 38% Marketbottom 36% Newsbottom 23% Funding: Raised $157M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) Product: 2 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 37/100 | $157M | 13 mo ago | Public | Peter Luo Founder & CEO | 15 | 26 patents Engineered antibody library platforms and Fc-modified bispecific therapeutics for cancer treatment | — |
| 8 | New Element Medicine Developer of drugs for various cancer | $152M | 34 mo ago | Series D | Shi Dongfang Founder & CEO | — | — | — |
| 9 | Legend Biotechnology Developer of cell therapy to treat cancer and infectious diseases | $150M | 40 mo ago | Public | Yuan Xu CEO | 1,576 | — | — |
| 10 | Impact Therapeutics Developer of small molecule therapeutics for the treatment of cancer 50Patents top 18%Funding top 21%Innovation top 23%Moat top 26% All 6 signals ▾Patentstop 18% Fundingtop 21% Innovationtop 23% Moattop 26% Globalbottom 43% Marketbottom 26% Patents: 226 patents matched (strict assignee match) · 118 filings since 2022 vs 76 in 2017-21 Funding: Raised $145M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $145M | 21 mo ago | Public | — | 7 | 226 patents Novel PARP, kinase, and DHX9 inhibitor chemotypes and solid formulations for oncology/CNS | — |
| 11 | Sinovent Developer of small molecule drugs for the treatment of tumour, CNS, autoimmunity, and infectious disease | $145M | 67 mo ago | Deadpooled | Jing Qiang Founder | 50 | — | — |
| 12 | Doma Pharmaceutical Technology Developer of drugs for the treatment of cancer | $142M | 50 mo ago | Series A | Shen Yuelei Chairman | — | — | — |
| 13 | MediLink Developer of antibody-drug conjugates for cancer treatment | $120M | 53 mo ago | Series B | Jiaqiang Cai Co-Founder & CSO | 49 49 → 60 (+22%) | — | — |
| 14 | Tot Biopharm Chinese oncology drug development and manufacturing company | $108M | 96 mo ago | Series B | — | — | — | — |
| 15 | Evopoint Developer of therapeutics for multiple diseases | $97M | 30 mo ago | Series E | Nianfeng Ju Co-Founder | — | — | — |
| 16 | Biosion Developer of antibody-based therapeutics to treat various diseases | $76M | 40 mo ago | Series B | Mingjiu Chen Founder & Chairman &CEO | 90 | 131 patents Therapeutic antibodies and fusion proteins for immune checkpoint and tumor antigen targeting | 1 launch |
| 17 | Accropeutics Developer of drugs for inflammation, autoimmune diseases, and cancer 57Funding top 20%Talent top 38%Market bottom 49%Global bottom 48% All 4 signals ▾Fundingtop 20% Talenttop 38% Marketbottom 49% Globalbottom 48% Funding: Raised $62.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $62M | 3 mo ago | Series C | Xiaohu Zhang Co-Founder & CEO | — | — | — |
| 18 | Qinhao Pharmaceutical Developer of small-molecule therapeutics for tumor and fibrosis | $31M | 54 mo ago | Series B | Kuifeng Wang Founder & CEO | 14 | — | — |
| 19 | Starna Therapeutics Developer of RNA-based drugs for multiple diseases 29Funding top 34%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 34% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $22M | 10 mo ago | Series B | Rongkuan Hu Founder | — | — | — |
| 20 | Hongyun Biotech Provider of therapeutics solution for the treatment of cancer and other rare diseases | $16M | 39 mo ago | Series B | Xin Huang CEO | — | — | — |
| 21 | Nanjing CART Medical Technologies Developer and provider of CAR T cell therapy related technologies and services | $10M | 54 mo ago | Series A | Enxiu Wang Founder | — | — | — |
| 22 | InnoBM Developer of immunotherapeutics for cancer treatment | $7M | 47 mo ago | Series A | Zhuang Liu Founder | — | — | — |
Top 12 Oncology companies in Jiangsu
#1
Series C · Suzhou, Jiangsu · founded 2017$62Mraised▾
Developer of drugs for inflammation, autoimmune diseases, and cancer. The pipeline includes AC-003 Receptor -interacting protein kinase1 for Idiopathic pulmonary fibrosis, Graft versus Host Disease, AC-101 for inflammatory bowel disease, AC-201, an allosteric TYK2/JAK1 inhibitor for psoriasis, and others.
- May 2026Series C$50M
- Mar 2025Series B$12M
#2
Public · Suzhou, Jiangsu · founded 2012 · 15 employees$157.4Mraised▾
Developer of immunotherapy for the treatment of cancer. It is developing antibodies which include ADG106 which is an agonist for CD137 in metastatic solid tumors, ADG126 targets CTLA4 for cancer therapy, and aADG116 targets epitope of CTLA4 in metastatic solid tumors and relapsed/refractory non-Hodgkin’s lymphoma.
- Jul 2025Post IPO$25M
- Jan 2020Series D$69M
- Mar 2018Series C$50M
- Jan 2016Series B$28M
#3
Series B · Suzhou, Jiangsu · founded 2021$22.1Mraised▾
Developer of RNA-based drugs for multiple diseases. The company focuses on the development of innovative drugs and vaccines with RNA as the core for infectious diseases, tumor immunology, and metabolic diseases.
- Oct 2025Series B$44M
- May 2022Series A$22.1M
- Dec 2021Angel—
#4
Public · Nanjing, Jiangsu · founded 2009 · 7 employees$145.2Mraised▾
Developer of small molecule therapeutics for the treatment of cancer. The company's product line include Senaparib is a PARP inhibitor for ovarian cancer maintenance therapy and small cell lung cancer, meeting primary endpoints in the FLAMES study for superior efficacy and safety. Other assets include WEE1 inhibitor IMP7068, ATR inhibitor IMP9064, and PARP1-selective inhibitor IMP1734 (collaborating with Eikon Therapeutics), alongside additional DDR inhibitors.
- Nov 2024Series D$34.5M
- Apr 2024Series D$55.2M
- Mar 2022Series D—
- Nov 2020Series C$50M
#5
Series C · Suzhou, Jiangsu · founded 2019$1.1Braised▾
Developer of mRNA-based therapeutics for cancer and infectious diseases. The company has developed proprietary technology platforms in mRNA design, in vitro synthesis, and LNP-based delivery systems to develop targeted therapies for infectious and immuno-oncology indications.
- May 2022Series C—
- Nov 2021Series C$300M
- Aug 2021Series C$720M
- Apr 2021Series B$91.6M
#6
Public · Suzhou, Jiangsu · founded 2011 · 5144 employees$535Mraised▾
Developer of antibody therapeutics for multiple diseases. It offers monoclonal and bispecific antibodies to treat several cancers such as non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, colorectal cancer, and lung cancer. Also, has antibody binding to TNF-α preventing it from activating TNF receptors, and will be used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s disease, and other autoimmune diseases.
- Aug 2022Post IPO$307.9M
- Oct 2019Post IPO$299.8M
- Apr 2018Series E$150M
- Nov 2016Series D$260M
#7
Series D · Zhenjiang, Jiangsu · founded 2012$152Mraised▾
Jiangsu develops drugs for various cancer and metabolic diseases. The company has various pipelined products like URAT-1 for gout and hyperuricemia disease and multiple targets drugs (ABP-6061 and ABP-431) for NASH, gastric cancer, colon cancer, and breast cancer.
- Oct 2023Series D$83M
- Jan 2022Series C$47.2M
- Jan 2020Series B$21.9M
- Jun 2018Series A—
#8
Series E · Suzhou, Jiangsu · founded 2017$97.3Mraised▾
Developer of therapeutics for multiple diseases. It offers a drug pipeline that includes BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and antibody-drug conjugates for the treatment of cancer, infectious disease, and metabolic disease.
- Feb 2024Series E$97.3M
#9
Public · Suzhou, Jiangsu · founded 2007 · 228 employees$200.8Mraised▾
Developer of nucleic acid drugs based on RNA interference (RNAi) technology. The company focuses on RNAi technology, drug discovery, siRNA design and screening, chemical modification, delivery technology, PD/PK study, safety evaluation, clinical trial, and other related aspects. Also, offers siRNA therapeutics against Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, HIV, etc.
- Jul 2022Series E$40M
- Apr 2020Series C$66.2M
- Dec 2019Series C$28.8M
- Mar 2017Series B$39.1M
#10
Public · Nanjing, Jiangsu · founded 2014 · 1576 employees$150.4Mraised▾
Developer of cell therapy to treat cancer and infectious diseases. The company focused on developing CAR-T cell therapies for hematologic malignancies, solid tumors, and infectious diseases.
- Apr 2023Post IPO$200M
- Mar 2020Series D$150.4M
#11
Series C · Nanjing, Jiangsu · founded 2017 · 400 employees$178Mraised▾
Provider of pharmaceuticals for cell therapies for oncology. Its technology involves CAR-T cell therapeutics for hematological malignant and its candidate like CT1038, RD102 and others.
- Jan 2023Series C—
- Sep 2021Series C$108M
- Mar 2020Series B$60M
#12
Series B · Nanjing, Jiangsu · founded 2017 · 90 employees$76.4Mraised▾
Developer of antibody-based therapeutics to treat various diseases. It offers BSI 045A drug candidate that targets IL4R immunizations for the treatments of asthma, atopic dermatitis, and others. Other products include BSI045B therapeutics for treating chronic obstructive pulmonary disease, BSI 038 drug candidate that targets CD40 for treating solid cancer, blood cancer, and many more.
- Apr 2023Series B—
- Dec 2022Series B$14.3M
- Dec 2021Series B$31.5M
- Dec 2020Series B$30.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology in Jiangsu is moving
A read on the academic research around Oncology in Jiangsu — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 553 papers.
- Jiangsu Province Hospital185
- Jiangsu University183
- Jiangsu Cancer Hospital120
- Affiliated Hospital of Jiangsu University96
- Northern Jiangsu People\'s Hospital47
- Tumor microenvironment1→83
- Cancer research2→58
- Cancer cell1→8
- Photothermal therapy1→4
- Microvesicles1→3
- Tumor microenvironment1→146
- Immune system1→123
- Cancer research3→103
- Metastasis1→27
- Tumor progression1→14
- Tumor microenvironment30
- Immunotherapy27
- Immune system20
- Cancer15
- Cancer immunotherapy12
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.